Key Indices


Top Stories
Company Results | AKR Corporindo (AKRA IJ/BUY/Rp1,390/Target: Rp1,600)
- AKRA's 9M26 net profit rose 34% yoy to Rp2.2t, reaching 77% of the market’s 2026 forecast, supported by recovering T&D margins, 93ha of land sales and accelerating utilities revenue. While 2026 earnings could approach the upper end of management's Rp2.9t guidance, we maintain conservative 2027 assumptions on T&D margins and land sales. Maintain BUY with a Rp1,600 target price, supported by a net cash balance sheet, a 7.2% dividend yield and JIIPE's longer-term growth potential.
Technical Analysis
Medco Energi Internasional | MEDC IJ
- Trading Buy Range: We have a technical Buy at Rp1,465, and take profit at Rp1,575.
Bank Mandiri | BMRI IJ
- Trading Buy Range: We have a technical Buy at Rp3,870, and take profit at Rp4,150.
Top Stories
Company Results | AKR Corporindo (AKRA IJ/BUY/Rp1,390/Target: Rp1,600)
- AKRA's 9M26 net profit rose 34% yoy to Rp2.2t, reaching 77% of the market’s 2026 forecast, supported by recovering T&D margins, 93ha of land sales and accelerating utilities revenue. While 2026 earnings could approach the upper end of management's Rp2.9t guidance, we maintain conservative 2027 assumptions on T&D margins and land sales. Maintain BUY with a Rp1,600 target price, supported by a net cash balance sheet, a 7.2% dividend yield and JIIPE's longer-term growth potential.
Technical Analysis
Medco Energi Internasional | MEDC IJ
- Trading Buy Range: We have a technical Buy at Rp1,465, and take profit at Rp1,575.
Bank Mandiri | BMRI IJ
- Trading Buy Range: We have a technical Buy at Rp3,870, and take profit at Rp4,150.
Key Indices


IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.





